AIM
XLRN

Assured Investment Management’s Acceleron Pharma XLRN Stock Holding History

Assured Investment Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,419
Closed -$95K – 1378
2018
Q1 		$95K Buy
+2,419
New +$103K ﹤0.01% 1056

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Assured Investment Management's XLRN Position: Q2 2018 in Review

Assured Investment Management sold out of Acceleron Pharma (XLRN) in Q2 2018, closing a stake of 2,419 shares — an estimated $95K sold.

Assured Investment Management first reported a position in XLRN in Q1 2018 and held it in 1 quarter. The position peaked at $95K in Q1 2018. 170 funds tracked by Wall St. Rank hold XLRN as of Q2 2018.

  • Assured Investment Management reported no remaining Acceleron Pharma position as of Q2 2018 after selling out during the quarter.
  • Assured Investment Management sold 2,419 Acceleron Pharma shares in Q2 2018, an estimated $95K.
  • Assured Investment Management first reported a position in Acceleron Pharma in Q1 2018 and held it in 1 quarter.
  • Assured Investment Management's Acceleron Pharma position peaked at $95K in Q1 2018.
  • 170 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2018.

Based on Assured Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.